Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2024 | 401 | 6.080 |
Why?
|
| Mastectomy | 7 | 2023 | 36 | 1.530 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 19 | 1.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 164 | 1.010 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2022 | 3 | 0.790 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2022 | 11 | 0.780 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 261 | 0.750 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 16 | 0.750 |
Why?
|
| Female | 19 | 2024 | 13266 | 0.740 |
Why?
|
| Mammaplasty | 1 | 2021 | 6 | 0.720 |
Why?
|
| Retrospective Studies | 10 | 2023 | 3122 | 0.690 |
Why?
|
| Humans | 21 | 2024 | 23572 | 0.630 |
Why?
|
| Hypercalcemia | 1 | 2019 | 7 | 0.610 |
Why?
|
| Carcinoma, Ductal | 1 | 2019 | 3 | 0.610 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 11 | 0.600 |
Why?
|
| Referral and Consultation | 2 | 2021 | 83 | 0.600 |
Why?
|
| Tamoxifen | 1 | 2019 | 30 | 0.590 |
Why?
|
| Stromal Cells | 1 | 2018 | 33 | 0.570 |
Why?
|
| Disease Management | 2 | 2019 | 101 | 0.570 |
Why?
|
| Mastectomy, Segmental | 2 | 2024 | 29 | 0.560 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 10 | 0.550 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 98 | 0.530 |
Why?
|
| Patient Compliance | 1 | 2018 | 146 | 0.530 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 4 | 0.510 |
Why?
|
| Body Mass Index | 1 | 2019 | 403 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 245 | 0.510 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 27 | 0.500 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 33 | 0.500 |
Why?
|
| Obesity | 1 | 2019 | 294 | 0.490 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 80 | 0.480 |
Why?
|
| Aged | 7 | 2023 | 7586 | 0.480 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 22 | 0.450 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 32 | 0.450 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 139 | 0.430 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 3770 | 0.430 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 359 | 0.410 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2024 | 23 | 0.410 |
Why?
|
| Decision Making | 1 | 2015 | 187 | 0.400 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 68 | 0.390 |
Why?
|
| Oocytes | 2 | 2009 | 6 | 0.360 |
Why?
|
| Cryopreservation | 2 | 2009 | 12 | 0.360 |
Why?
|
| Postoperative Complications | 1 | 2016 | 837 | 0.340 |
Why?
|
| Case-Control Studies | 2 | 2023 | 505 | 0.310 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1493 | 0.300 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2008 | 1 | 0.280 |
Why?
|
| Infertility, Female | 1 | 2007 | 21 | 0.270 |
Why?
|
| Quality of Life | 2 | 2022 | 565 | 0.270 |
Why?
|
| Adult | 7 | 2022 | 7178 | 0.270 |
Why?
|
| Prognosis | 2 | 2019 | 749 | 0.220 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2023 | 16 | 0.200 |
Why?
|
| Time Factors | 4 | 2019 | 1295 | 0.200 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 101 | 0.190 |
Why?
|
| Mutation | 1 | 2023 | 330 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2024 | 204 | 0.180 |
Why?
|
| Length of Stay | 1 | 2023 | 305 | 0.170 |
Why?
|
| Middle Aged | 4 | 2023 | 8155 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 82 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2019 | 3095 | 0.160 |
Why?
|
| Acellular Dermis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Breast Implantation | 1 | 2019 | 3 | 0.160 |
Why?
|
| Breast Implants | 1 | 2019 | 5 | 0.150 |
Why?
|
| Mammography | 1 | 2019 | 43 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 295 | 0.140 |
Why?
|
| Phyllodes Tumor | 1 | 2017 | 2 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2017 | 12 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2016 | 51 | 0.130 |
Why?
|
| Needles | 1 | 2016 | 17 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 648 | 0.120 |
Why?
|
| Biopsy | 1 | 2015 | 194 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 908 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 366 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 606 | 0.090 |
Why?
|
| Young Adult | 1 | 2016 | 1747 | 0.090 |
Why?
|
| Amenorrhea | 1 | 2009 | 2 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 24 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 199 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2007 | 14 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2008 | 203 | 0.060 |
Why?
|
| Breast | 1 | 2024 | 23 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2024 | 63 | 0.050 |
Why?
|
| General Surgery | 1 | 2024 | 52 | 0.050 |
Why?
|
| Male | 1 | 2019 | 12777 | 0.050 |
Why?
|
| Curriculum | 1 | 2024 | 132 | 0.050 |
Why?
|
| Adolescent | 1 | 2008 | 1953 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2024 | 202 | 0.050 |
Why?
|
| Esthetics | 1 | 2019 | 11 | 0.040 |
Why?
|
| Radiologists | 1 | 2019 | 8 | 0.040 |
Why?
|
| Pectoralis Muscles | 1 | 2019 | 16 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 29 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 41 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 112 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 82 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2019 | 114 | 0.040 |
Why?
|
| Wound Healing | 1 | 2019 | 123 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 166 | 0.040 |
Why?
|
| Surgeons | 1 | 2019 | 79 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 379 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 316 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 556 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 424 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1466 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 62 | 0.020 |
Why?
|